GSK Adds Detailed Clinical Trial Data to Multi-Sponsor Request System as Part of Commitment to Data Transparency
GlaxoSmithKline (GSK) has added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system (clinicalstudydatarequest.com) that includes studies from multiple organisations.
Last year, GSK became the first company to launch an online system enabling external researchers to request access to the detailed data that sit behind its clinical trial results. More than 450 studies have now been made available on the new site. GSK’s patient-level data transparency commitments remain unchanged through the new multi-sponsor request system:
◾GSK is continuing to post studies going back to the formation of GSK in 2000.
◾Studies are made available once a medicine has been approved by regulators or terminated from development and the study has been accepted for publication (studies that do not progress to publication will also be included).
◾Researchers can ask about the availability of data they are interested in from studies not yet listed on the site.
◾The arm’s length review panel who have been reviewing proposals through GSK’s site since May 2013 will continue its role and will now review proposals that include studies from other sponsors. Up to 30 November 2013, 16 requests for data had been received by the review panel. Twelve requests had been approved, with four being processed. None had been turned down.
GSK will regularly add studies to the site. The next major update, when additional new and historic studies will be added, is planned for Q1 2014.
James Shannon, GSK’s Chief Medical Officer, said: “Our commitment to transparency of clinical trial data reflects our wish to help advance scientific understanding and enable the scientific community to learn from the research we have undertaken. Enabling researchers to request the studies they are interested in from multiple organisations through one system will, we hope, help further research.
“Our ultimate aim remains unchanged and that is to see a broad system developed that brings together data from many organisations and is also run by an independent third party who would be responsible for managing the review of research proposals. This initiative is an important step towards that aim.”
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance